Clinical and demographic characteristics of patients with and without clinical benefit from immune checkpoint blockade therapy
| Variables | Patients with clinical benefit n (%) | Patients with no clinical benefit n (%) |
| Total patients | 4 (25) | 12 (75) |
| Age at diagnosis (years), median (mean), range | 50.5 (49.3), 34–62 | 51.5 (53.5), 38–69 |
| Stage at diagnosis | ||
| I | 0 | 2 (17) |
| II | 0 | 1 (8) |
| III | 3 (75) | 5 (42) |
| IV | 1 (25) | 4 (33) |
| Neoadjuvant chemotherapy | ||
| Yes | 2 (50) | 2 (17) |
| No | 2 (50) | 10 (83) |
| Surgery outcome | ||
| CGR | 0 | 5 (42) |
| OD | 2 (50) | 3 (25) |
| SD | 2 (50) | 1 (8) |
| Unknown | 0 | 2 (17) |
| No cytoreductive surgery | 0 | 1 (8) |
| ICB target | ||
| PD-1/PD-L1 | 1 (25) | 4 (33) |
| PD-1/PD-L1 +CTLA-4 | 3 (75) | 4 (33) |
| PD-1/PD-L1 +targeted therapy | 0 | 4 (33) |
| ICB duration (days), median (mean), range | 383 (340), 21–574 | 51.5 (57.6), 14–153 |
| Discontinuation reason* | ||
| POD | 2 (50) | 12 (100) |
| Adverse event | 1 (25) | 1 (8) |
| Still on treatment | 1 (25) | 0 |
| TTF (days), median (mean), range | 402 (776), 358–1568† | 76 (87), 27–167 |
| PFS (days), median (mean), range | 387 (754), 336–1538† | 53 (70), 21–151 |
| Number of treatment lines | ||
| Prior to ICB | 3 (3.4), 1–7 | 3 (2.9), 1–7 |
| After ICB | 2 (1.6), 0–4 | 1 (1.2), 0–6 |
*One patient discontinued treatment due to simultaneous POD and adverse event.
†Does not include TTF/PFS for patient 10 and patient 12, both of whom remain disease free and have not started next-line therapy at the time of data freeze, when censoring occurred.
CGR, complete gross resection; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; ICB, immune checkpoint blockade; OD, optimal debulking; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival; POD, progression of disease; SD, suboptimal debulking; TTF, time to treatment failure.